NervgenP's profile picture. Restoring Life’s Potential by Enabling the Nervous System to Repair Itself after Neurologic Trauma and Disease

NervGen Pharma Corp.

@NervgenP

Restoring Life’s Potential by Enabling the Nervous System to Repair Itself after Neurologic Trauma and Disease

NervGen Pharma today announced that the company's common shares have been approved for listing on Nasdaq and will begin trading today under the symbol “NGEN.” nervgen.com/nervgen-pharma… #SCI #SpinalCordInjury

NervgenP's tweet image. NervGen Pharma today announced that the company's common shares have been approved for listing on Nasdaq and will begin trading today under the symbol “NGEN.”

nervgen.com/nervgen-pharma…

#SCI #SpinalCordInjury

Thank you, @Forbes and @TheAlexKnapp, for featuring NVG-291 in this week’s edition of The Prototype!


NervGen CEO Adam Rogers spoke with @BioSpace about the unprecedented CONNECT SCI data showing NVG-291 improved function, independence & quality of life in chronic #SCI with reported durability up to 1 year after the 16-week study period. biospace.com/drug-developme…

NervgenP's tweet image. NervGen CEO Adam Rogers spoke with @BioSpace about the unprecedented CONNECT SCI data showing NVG-291 improved function, independence & quality of life in chronic #SCI with reported durability up to 1 year after the 16-week study period.
 
biospace.com/drug-developme……

NervGen reports its third quarter 2025 financial results and provides business updates. Read the full release here: nervgen.com/nervgen-pharma… #SCI #SpinalCordInjury #News

NervgenP's tweet image. NervGen reports its third quarter 2025 financial results and provides business updates. 

Read the full release here: nervgen.com/nervgen-pharma…

#SCI #SpinalCordInjury #News

NervGen today announced expanded CONNECT SCI Study data demonstrating unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic SCI. nervgen.com/nervgen-pharma… #SCI #SpinalCordInjury #News

NervgenP's tweet image. NervGen today announced expanded CONNECT SCI Study data demonstrating unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic SCI. 

nervgen.com/nervgen-pharma… 

#SCI #SpinalCordInjury #News

NervGen today announced it is conducting a non-brokered private placement. The financing will include participation from new and existing investors, including SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation. nervgen.com/nervgen-pharma… #SCI #SpinalCordInjury

NervgenP's tweet image. NervGen today announced it is conducting a non-brokered private placement. The financing will include participation from new and existing investors, including SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation.

nervgen.com/nervgen-pharma…

#SCI #SpinalCordInjury

Our CEO Adam Rogers, MD, will join the #BioFuture2025 panel, “Rewiring Minds: Breakthroughs in Brain & CNS Health,” exploring how advances in neuroscience are transforming healthcare. 🗓️ Oct 13 | 🕙 11 AM |📍 NYC biofuture.com #SCI #SpinalCordInjury #CNS #Biotech

NervgenP's tweet image. Our CEO Adam Rogers, MD, will join the #BioFuture2025 panel, “Rewiring Minds: Breakthroughs in Brain & CNS Health,” exploring how advances in neuroscience are transforming healthcare.

🗓️ Oct 13 | 🕙 11 AM |📍 NYC

biofuture.com 

#SCI #SpinalCordInjury #CNS #Biotech

It's #SpinalCordInjuryAwarenessMonth! Catch up with our CEO, Adam Rogers, MD, on the @ProgressPotent1 podcast with @irat1onal where he highlights NVG-291, the urgent need in SCI, and our mission to transform the lives of people living with #SCI. youtube.com/watch?v=9tG1_l…

NervgenP's tweet image. It's #SpinalCordInjuryAwarenessMonth! Catch up with our CEO, Adam Rogers, MD, on the @ProgressPotent1 podcast with @irat1onal where he highlights NVG-291, the urgent need in SCI, and our mission to transform the lives of people living with #SCI.

youtube.com/watch?v=9tG1_l…

NervGen Pharma Corp. reposted

📊 The "NVG-291 in Spinal Cord Injury Subjects" trial at Shirley Ryan AbilityLab is currently the most inquired trial on SCITrialsFinder.NET with almost 1500 inquiries via our website as of Q2 2025. 💡 NervGen also just published further updates: nervgen.com/nervgen-pharma…

SCITrialsFinder's tweet image. 📊 The "NVG-291 in Spinal Cord Injury Subjects" trial at Shirley Ryan AbilityLab is currently the most inquired trial on SCITrialsFinder.NET with almost 1500 inquiries via our website as of Q2 2025.

💡 NervGen also just published further updates: nervgen.com/nervgen-pharma…

Today is #WorldSpinalCordInjuryDay. We’re developing NVG-291, a first-in-class therapy, and the first pharmacologic candidate designed to enable nervous system repair—because recovery is possible for those living with spinal cord injury. nervgen.com #WorldSCIDay


NervGen today announced its second quarter 2025 financial results, including a letter to shareholders from Adam Rogers, MD, the Company’s Chairman and Interim CEO, providing a detailed business update. nervgen.com/nervgen-pharma… #SCI #News

NervgenP's tweet image. NervGen today announced its second quarter 2025 financial results, including a letter to shareholders from Adam Rogers, MD, the Company’s Chairman and Interim CEO, providing a detailed business update.

nervgen.com/nervgen-pharma…

#SCI #News

NervGen today announced positive preclinical results of two @DeptofDefense sponsored studies in models of blast-induced sensorineural hearing loss and peripheral nerve injury, reinforcing the broad therapeutic application of NVG-291. nervgen.com/nervgen-pharma… #SCI #News

NervgenP's tweet image. NervGen today announced positive preclinical results of two @DeptofDefense sponsored studies in models of blast-induced sensorineural hearing loss and peripheral nerve injury, reinforcing the broad therapeutic application of NVG-291.

nervgen.com/nervgen-pharma…

#SCI #News

NervGen announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Read the full release: nervgen.com/nervgen-announ…#SCI #SpinalCordInjury #news


“We achieved our primary endpoint demonstrating improved hand-motor connectivity and showed positive improvement in hand function in the chronic cohort of our Phase 1b/2a trial,” said Mike Kelly, NervGen’s President and Chief Executive Officer. Chief Medical Officer, Dr. Daniel…


NervGen announced the results from the chronic cohort (1-10 years post-injury) of its Phase 1b/2a clinical trial evaluating NVG-291 in spinal cord injury. Read more about the results: bit.ly/1b2aChronicCoh… #SCI #SpinalCordInjury #news

NervgenP's tweet image. NervGen announced the results from the chronic cohort (1-10 years post-injury) of its Phase 1b/2a clinical trial evaluating NVG-291 in spinal cord injury.

Read more about the results: bit.ly/1b2aChronicCoh…

#SCI #SpinalCordInjury #news

#DYK: NervGen and Shirley Ryan AbilityLab are conducting a clinical trial in #SCI. Watch to learn more about our unique trial design using electrophysiology. bit.ly/NervGenBreakin… #spinalcordinjury #clinicaltrial #science


Loading...

Something went wrong.


Something went wrong.